Gritstone bio, CEPI Expand COVID-19 Vaccine Agreement to Combat Omicron Variant

Gritstone bio Inc GRTS and Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their agreement to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant. 

  • CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone's Omicron vaccine candidate in South Africa, where a CEPI-funded trial of Gritstone's Beta variant COVID-19 vaccine is due to begin shortly. 
  • The SARS-CoV-2 T cell epitopes (TCEs) administered within Gritstone's SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform's potential to address both Omicron and future variants of concern.
  • CEPI is already funding up to $20.6 million to support preclinical studies, manufacturing process optimization, and a Phase 1 trial of Gritstone's Beta variant vaccine candidate.
  • The funding announced today will expand the Phase 1 trial to include additional arms to evaluate an Omicron-specific version of the vaccine. 
  • Gritstone has commenced manufacturing its SAM vaccine to target the Omicron variant specifically, and the Omicron arms of the Phase 1 trial are expected to begin in Q2 2022.
  • Price Action: GRTS shares down 0.60% at $11.51 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingSmall CapGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!